(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders.
Jyoti SihagVincenzo Di MarzoPublished in: Lipids in health and disease (2022)
The discovery of the endocannabinoidome (eCBome) is evolving gradually with yet to be elucidated functional lipid mediators and receptors. The diet modulates these bioactive lipids and the gut microbiome, both working in an entwined alliance. Mounting evidence suggests that, in different ways and with a certain specialisation, lipid signalling mediators such as N-acylethanolamines (NAEs), 2-monoacylglycerols (2-MAGs), and N-acyl-amino acids (NAAs), along with endocannabinoids (eCBs), can modulate physiological mechanisms underpinning appetite, food intake, macronutrient metabolism, pain sensation, blood pressure, mood, cognition, and immunity. This knowledge has been primarily utilised in pharmacology and medicine to develop many drugs targeting the fine and specific molecular pathways orchestrating eCB and eCBome activity. Conversely, the contribution of dietary NAEs, 2-MAGs and eCBs to the biological functions of these molecules has been little studied. In this review, we discuss the importance of (Wh) olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N) utrition (WHEN), in the management of obesity and related disorders.
Keyphrases
- weight loss
- fatty acid
- blood pressure
- insulin resistance
- metabolic syndrome
- high fat diet induced
- type diabetes
- weight gain
- amino acid
- chronic pain
- healthcare
- small molecule
- bipolar disorder
- air pollution
- neuropathic pain
- physical activity
- pain management
- mild cognitive impairment
- glycemic control
- heart rate
- cancer therapy
- adipose tissue
- body mass index
- body weight
- drug delivery
- single molecule
- depressive symptoms
- tissue engineering